Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

1024687

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that there is no disparity in access to treatments for rare diseases between the UK and economically similar countries in Europe.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	202087
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>The Government is committed to the safe and effective regulation of medicines in the United Kingdom; ensuring patients and the public have fast access to new, innovative medicines, including medicines for rare diseases.</p><p> </p><p>The agreement of an implementation period will ensure that access to medicines continues, and patient safety is maintained, in both the UK and European Union markets. Beyond that, the Political Declaration sets out a plan for a free trade area for goods, underpinned by deep regulatory co-operation, as well as a joint commitment to explore close cooperation with the European Medicines Agency.</p><p> </p><p>The Government also continues to prepare for the unlikely outcome that we leave the EU without any deal in March 2019. The Department has been engaging with all pharmaceutical companies that supply the United Kingdom with pharmacy or prescription-only medicines from, or via, the EU/European Economic Area, on their contingency plans in the event of a no deal EU exit.</p><p> </p><p>Whatever the exit scenario, we will continue to ensure that UK patients are able to access the best and most innovative medicines including medicines for rare diseases and that their safety is protected.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/12/2018 17:36:24 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4249 label Biography information for Anne Marie Morris

1024696

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	North Staffordshire Combined Healthcare NHS Trust
house id	1
legislature	25259 pref label House of Commons
question text	o ask the Secretary of State for Health and Social Care, what correspondence he has received from (a) local authorities in Staffordshire and (b) the Midlands Partnership Foundation Trust on the future of the North Staffordshire Combined Healthcare Trust; and if he will place a copy of such correspondence in the Library.
tabling member constituency	Stoke-on-Trent Central
tabling member printed	Gareth Snell
uin	202089
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>The Department has received one item of relevant correspondence from a local authority in Staffordshire, which is attached. There has been no correspondence from the Midlands Partnership Foundation Trust on the future of the North Staffordshire Combined Healthcare Trust.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 18/12/2018 17:00:30 answering member 1585 label Biography information for Stephen Hammond attachment 1 file name Staffs County Council.pdf title Letter Staffs County Council
tabling member	4595 label Biography information for Gareth Snell

1024698

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Orphan Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he is taking steps to introduce a revised definition for ultra-orphan medicine.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	202090
answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>Currently, rare diseases are defined as conditions affecting no more than five in 10,000 people in the European Union. The new European Clinical Trial Regulation (Regulation (EU) No 536/2014) will introduce an ‘ultra-rare’ condition and states that clinical trials for the development of orphan medicinal products and those of medicines affecting no more than one person in 50,000 in the EU (ultra-rare diseases) should be fostered, and in such areas, a rapid yet in-depth assessment is of particular importance. The new clinical trials regulation is expected to be implemented in the EU in late 2020. The Government has confirmed that United Kingdom law will remain aligned with the parts of the new EU clinical trials Regulation that are within the UK’s control.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/12/2018 17:10:46 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4488 label Biography information for Martyn Day

1024700

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the UK remains a world leader for the treatment of rare diseases after the UK leaves the EU.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	202091
answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>The Government is committed to the safe and effective regulation of medicines in the United Kingdom; ensuring patients and the public have fast access to new, innovative medicines, including medicines for rare diseases.</p><p> </p><p>The agreement of an implementation period will ensure that access to medicines continues, and patient safety is maintained, in both the UK and European Union markets. Beyond that, the Political Declaration sets out a plan for a free trade area for goods, underpinned by deep regulatory co-operation, as well as a joint commitment to explore close cooperation with the European Medicines Agency.</p><p> </p><p>The Government also continues to prepare for the unlikely outcome that we leave the EU without any deal in March 2019. The Department has been engaging with all pharmaceutical companies that supply the United Kingdom with pharmacy or prescription-only medicines from, or via, the EU/European Economic Area, on their contingency plans in the event of a no deal EU Exit.</p><p> </p><p>Whatever the exit scenario, we will work to ensure that the UK will remain a world leader for the treatment of rare diseases after the UK leaves the EU, that UK patients are able to access the best and most innovative medicines including medicines for rare diseases and that their safety is protected. The UK life sciences industry has much to offer in creating, developing, trialing and commercialising medicines that will benefit UK patients and strengthen the ability of the UK to compete internationally.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/12/2018 17:07:43 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4488 label Biography information for Martyn Day

1024713

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of patients waiting at least three weeks to see a GP.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	202044
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>The Government has committed to ensuring everyone across the country has easier and more convenient access to general practice services, including appointments in the evenings and weekends.</p><p> </p><p>The latest National Health Service planning guidance, issued by NHS England in February 2018, brought forward the deadline for clinical commissioning groups to provide extended access to general practice services to 1 October 2018, to ensure additional capacity is in place ahead of winter 2018. This includes ensuring that access is available during peak times of demand, including bank holidays and across the Easter, Christmas and New Year periods.</p><p> </p><p>NHS England and Health Education England (HEE) are working together with the profession to increase the general practitioner (GP) workforce. This includes measures to boost recruitment, address the reasons why GPs are leaving the profession, and encourage GPs to return to practice.</p><p> </p><p>The number of doctors entering GP speciality training has been increasing year on year, this year HEE recruited the highest number of GP trainees ever - 3,473 GP trainees against a target of 3,250, a 10% increase on last year.</p><p> </p><p>Greater skill mix is also key to releasing capacity in general practice, we have committed to investment in the multidisciplinary workforce in general practice. As of June 2018, there were</p><p>over 3,300 additional clinical staff, excluding GPs, working in general practice since 2015; consisting of over 500 more nurses and 2,800 more other direct patient care.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/12/2018 17:06:19 answering member 4067 label Biography information for Steve Brine
tabling member	308 label Biography information for Mr Jim Cunningham

1024789

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ovarian Cancer: Staffordshire
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) increase early diagnosis rates for ovarian cancer and (b) increase access to treatment for ovarian cancer in specialist centres in Staffordshire.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	202081
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>Public Health England (PHE) has run a number of ‘Be Clear on Cancer’ campaigns to help improve early detection of cancer including ovarian cancer. In 2014 PHE ran a pilot regional ovarian cancer campaign in the North West of England. In 2017, PHE ran a pilot campaign in the East and West Midlands which focussed on a range of abdominal symptoms, such as diarrhoea, bloating and discomfort that can be indicative of a number of cancers, including ovarian cancer. NHS England has invested over £200 million between 2017 and 2019, supporting Cancer Alliances to accelerate diagnosis and enhance quality of life.</p><p> </p><p>Staffordshire clinical commissioning groups commission diagnostic services for ovarian cancer fully in line with National Institute for Health and Care Excellence guidelines across the whole sustainability and transformation partnership.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/12/2018 17:04:54 answering member 4067 label Biography information for Steve Brine
tabling member	1436 label Biography information for Paul Farrelly

1024805

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Smoking: Death
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has set a target for reducing the number of deaths due to smoking-related conditions in the lifetime of this Parliament.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	202051
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>The Government has not set a target for reducing the number of deaths due to smoking related conditions. Last year we published ‘Towards a smoke-free generation: a Tobacco Control Plan for England’, which committed the Government to achieve a smoke-free generation. Over the course of this Parliament the Government aims to reduce smoking prevalence from:</p><p>- 15.5% to 12% amongst adults;</p><p>- 10.7% to 6% amongst pregnant women; and</p><p>- 8% to 3% amongst 15-year olds who regularly smoke.</p><p> </p><p>The Government also aims to reduce the inequality gap in smoking prevalence between those in routine and manual occupations and the general population.</p><p> </p><p>Death rates due to smoking have been falling since 2006 and evidence suggests that quitting smoking will improve one’s life expectancy, even if quitting happens later in life.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/12/2018 17:01:16 answering member 4067 label Biography information for Steve Brine
tabling member	1409 label Biography information for Mr Gregory Campbell

1024860

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Speech and Language Therapy: Children and Young People
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what discussions they plan to have with NHS Clinical Commissioners about ensuring that speech and language therapy service specifications (1) require speech and language therapy services to have a pathway for when a child or young person is not brought to an appointment, including for children and young people who are known to be at higher risk of poorer outcomes or safeguarding issues, (2) ensure and appropriately resource speech and language therapy services to provide support in settings that meet the needs of the children or young people and their parents and carers, and (3) monitor and report on the number of children and young people who are discharged from speech and language therapy services because they were not brought to an appointment.
tabling member printed	Lord Shinkwin
uin	HL12301
answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>We have no plans at present to hold discussions with NHS Clinical Commissioners concerning speech and language therapy service specifications. Clinical commissioning groups have responsibility for commissioning services to meet the needs of their local population, drawing on National Institute for Health and Care Excellence guidance to agree the specifications for communication support. The protection and safeguarding of children and young people from harm is of paramount importance to all parts for the health care system. All providers should have their own governance arrangements in place for responding to non-attendance at appointments.</p> answering member printed Lord O'Shaughnessy question first answered 20/12/2018 12:26:36 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4557 label Biography information for Lord Shinkwin

1024861

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Negligence
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they have undertaken forward planning or modelling to estimate the cost of clinical negligence claims in the period to 2020–21.
tabling member printed	Lord Storey
uin	HL12302
answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>NHS Resolution handles clinical negligence claims on behalf of National Health Service organisations and independent sector providers of NHS care in England.</p><p>NHS Resolution annually reviews and updates five-year forecasts for the cost of clinical negligence following an actuarial review of activity and key assumptions that underpin those costs, e.g. claims inflation, claims volumes. These key assumptions are published in the organisation’s Annual Report and Accounts. Clinical negligence costs relate to four indemnity schemes operated by NHS Resolution: Clinical Negligence Scheme for Trusts (CNST), which covers NHS providers of secondary health care, and the Existing Liabilities, Ex-Regional Health Authorities, and the Department of Health and Social Care’s Clinical schemes, all of which relate to legacy organisations.</p><p>The cost of clinical negligence claims covered by the figures in this response are damages, claimant legal costs, defence legal costs, and NHS Resolution’s administration costs. The costs reported here do not include costs incurred locally by NHS providers in dealing with claims, such as their own administration costs.</p><p>NHS Resolution’s Statement of Net Expenditure estimates costs of clinical negligence at £11.7 billion in its 2020-21 accounts. This the total of the two dimensions in relation to “costs” in the context of Government budgeting:</p><p>- Department Expenditure Limit costs – these are the costs of settling claims during the financial year and the administration of those claims. This is estimated to be £2.6 billion for 2020-21; and</p><p>- Annually Managed Expenditure costs – this is the change in the value of the liability arising from clinical negligence claims, both from those that have been received, and those that are expected to be received in relation to incidents up to 31 March 2021. This is estimated to be £9.1 billion for 2020-21.</p><p> </p><p>The costs for 2020-21 have been estimated on the basis of the current personal injury discount rate of minus 0.75%. However, once the Civil Liability Bill becomes law, the Lord Chancellor is expected to review the rate promptly. The figures provided here may therefore, change as a result. NHS Resolution will also review its five-year forecasts again following the production of its 2018-19 Annual Report and Accounts, and any changes in the underpinning actuarial assumptions are likely to result in revised projections. The figures quoted should therefore be considered as broad estimates based on the latest available information and subject to change in the future.</p><p>Notes:</p><p>The Department Expenditure Limit costs are lower than the £3.2 billion costs for CNST only reported by the National Audit Office in their report <em>Managing the costs of clinical negligence in trusts</em>, published in September 2017. The £3.2 billion represents the 2016 forecast for CNST based on a personal injury discount rate of 2.5%. Actuarial reviews of assumptions undertaken by NHS Resolution in 2017 and 2018 have resulted in favourable movements in key assumptions.</p><p>The figures provided do not include claims brought against general practitioners, who are covered by separate indemnity arrangements through medical defence organisations and for which data is not centrally available.</p> answering member printed Lord O'Shaughnessy question first answered 20/12/2018 12:30:07 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4238 label Biography information for Lord Storey

1023896

registered interest
date	12/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genito-urinary Medicine: Lambeth
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what were the average waiting times to be seen by a health worker in sexual health clinics in Lambeth were in (a) 2010, (b) 2015 and 2018.
tabling member constituency	Streatham
tabling member printed	Chuka Umunna
uin	201750
answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>Waiting times for sexual health services are not monitored centrally. Local authorities are best placed to understand and meet the public health needs of their local communities.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/12/2018 17:12:43 answering member 4067 label Biography information for Steve Brine
tabling member	4128 label Biography information for Chuka Umunna